Civic AI
Procurement intelligence
Federal contract award
THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE ARTICLE G.7. INDIRECT COST RATE AND 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS.
MAPP BIOPHARMACEUTICAL, INC. · Department of Health and Human Services
- Value
- $3,004,498
- Start
- Mar 20, 2024
- End
- Dec 31, 2032
- Action date
- May 12, 2026
- PIID
- 75A50124C00003
- Status
- active
- NAICS
- 541714 · RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
- Place of performance
- SAN DIEGO, CA
- Award type
- DEFINITIVE CONTRACT
Description
THE PURPOSE OF THIS NO-COST MODIFICATION IS TO REVISE ARTICLE G.7. INDIRECT COST RATE AND 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS.
Need modifications, related awards, and vendor peers? Open the full award workspace.